Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Needham Maintains Buy on Azenta, Lowers Price Target to $115

Needham analyst David Saxon maintains Azenta (NASDAQ:AZTA) with a Buy and lowers the price target from $155 to $115.

byBenzinga Newsdesk

February 9, 2022

1 minute read

Needham analyst David Saxon maintains Azenta (NASDAQ:AZTA) with a Buy and lowers the price target from $155 to $115.

News

Yield10 Bioscience Reports Field Test Results Show Seed Oil Content Increase In Camelina, Canola

By Benzinga Newsdesk

Today, 6:03 AM

Yield10 Bioscience, Inc. (NASDAQ:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that 2021 field test results show that the trait C3020 tested in Camelina

YTEN

Maxim Group Maintains Buy on Euroseas, Lowers Price Target to $36

By Benzinga Newsdesk

Today, 6:03 AM

Maxim Group analyst Tate Sullivan maintains Euroseas (NASDAQ:ESEA) with a Buy and lowers the price target from $42 to $36.

ESEA

Ex-Tesla Australia Head Pleads Guilty To Insider Trading, Bought Piedmont Shares And Made Profit Of $28,883

By Navdeep Yadav

Today, 6:03 AM

The former head of Elon Musk-led Tesla Inc‘s (NASDAQ:TSLA) Australian unit pleaded guilty to two counts of insider…

PLL

Oppenheimer Maintains Outperform on Ingevity, Raises Price Target to $95

By Benzinga Newsdesk

Today, 6:03 AM

Oppenheimer analyst Ian Zaffino maintains Ingevity (NYSE:NGVT) with a Outperform and raises the price target from $85 to $95.

NGVT

Needham Maintains Buy on Azenta, Lowers Price Target to $115

Related Posts

Yield10 Bioscience Reports Field Test Results Show Seed Oil Content Increase In Camelina, Canola

Maxim Group Maintains Buy on Euroseas, Lowers Price Target to $36

Ex-Tesla Australia Head Pleads Guilty To Insider Trading, Bought Piedmont Shares And Made Profit Of $28,883

Oppenheimer Maintains Outperform on Ingevity, Raises Price Target to $95